{"entity":{"id":"paper-doebele-entrectinib-ntrk-lancet-oncol-2020","kind":"paper","name":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials","aka":[],"tldr":"Entrectinib, a TRK and ROS1 inhibitor that enters the brain, shrank tumours in more than half of patients with NTRK fusion-positive cancers of ten types and controlled brain metastases, leading to a tumour-agnostic approval alongside larotrectinib.","summary":"Integrated analysis of 54 adults with NTRK fusion-positive solid tumours from the ALKA-372-001, STARTRK-1 and STARTRK-2 trials treated with entrectinib.\n\nObjective response was 57 percent with a median duration of response of 10 months and intracranial response in half of the patients with brain metastases; toxicity included weight gain, dizziness and dysgeusia.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2020","url":"https://doi.org/10.1016/S1470-2045(19)30691-6"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31838007/"}],"tags":[],"related":[],"cancers":["ntrk-fusion-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["entrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(19)30691-6","pmid":"31838007","authors":"Doebele RC, Drilon A, Paz-Ares L, et al.","paperType":"observational","findings":["Objective response 57 percent; median duration of response 10 months.","Intracranial response in 50 percent of patients with brain metastases."],"whatItMeans":"Entrectinib is an approved tumour-agnostic TRK inhibitor with an advantage in patients with brain metastases, and it is also approved for ROS1-positive lung cancer.","caveats":["Small pooled population; median progression-free survival 11 months."],"changedPractice":true,"participants":54},"route":"/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/","neighbours":{"cancer":[{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/"}],"drug":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}